Clinical Trial Update: Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the MEK inhibitor GSK1120212 (trametinib) in patients with BRAF mutation-positive melanoma previously treated with or without a BRAF …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• GSK1120212 (trametinib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-03-31